We are live on
!
Find out more
SC
Stempoint Capital Portfolio holdings
AUM
$522M
1-Year Est. Return
281.95%
This Fund
S&P 500
This Quarter
Est. Return
+25.39%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$375M
AUM Growth
–
Cap. Flow
+$315M
Cap. Flow
% of AUM
83.93%
Top 10 Holdings %
Top 10 Hldgs %
39.49%
Holding
67
New
67
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$21.1M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$16.8M |
| 3 |
ACLX
Arcellx
ACLX
|
+$14.1M |
| 4 |
Immunovant
IMVT
|
+$11.8M |
| 5 |
MRUS
Merus
MRUS
|
+$11.7M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Roivant Sciences
ROIV
$25.2B
| $24.4M | 6.5% |
+2,169,116
| New | +$21.1M |
|
|
2
Syndax Pharmaceuticals
SNDX
$1.84B
| $23.7M | 6.31% |
+1,094,494
| New | +$16.8M |
|
|
ACLX
3
DELISTED
Arcellx
ACLX
| $17.4M | 4.64% |
+313,604
| New | +$14.1M |
|
|
MRUS
4
DELISTED
Merus
MRUS
| $13.8M | 3.68% |
+501,806
| New | +$11.7M |
|
|
5
Immunovant
IMVT
$8.09B
| $13.6M | 3.62% |
+322,015
| New | +$11.8M |
|
|
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
| $12.2M | 3.27% |
+862,815
| New | +$9.8M |
|
7
Protagonist Therapeutics
PTGX
$8.75B
| $11.8M | 3.14% |
+513,681
| New | +$8.99M |
|
8
Immatics
IMTX
$1.24B
| $10.7M | 2.87% |
+1,020,214
| New | +$9.39M |
|
9
BridgeBio Pharma
BBIO
$16.5B
| $10.3M | 2.74% |
+253,948
| New | +$7.63M |
|
10
Cabaletta Bio
CABA
$439M
| $10.2M | 2.73% |
+450,706
| New | +$7.58M |
|
11
MoonLake Immunotherapeutics
MLTX
$1.59B
| $10.1M | 2.7% |
+167,851
| New | +$8.65M |
|
12
CALL
argenx
ARGX
$57.4B
| $10.1M | 2.69% |
+26,484
| New | +$12.3M |
|
13
Merck
MRK
$324B
| $9.7M | 2.59% |
+89,016
| New | +$9.24M |
|
14
Johnson & Johnson
JNJ
$634B
| $9.56M | 2.55% |
+61,011
| New | +$9.36M |
|
15
Crinetics Pharmaceuticals
CRNX
$8.86B
| $8.88M | 2.37% |
+249,575
| New | +$7.65M |
|
16
Eli Lilly
LLY
$1.07T
| $8.78M | 2.34% |
+15,067
| New | +$8.79M |
|
17
VistaGen Therapeutics
VTGN
$9.29M
| $8.76M | 2.34% |
+1,790,182
| New | +$6.77M |
|
18
Arcutis Biotherapeutics
ARQT
$3.42B
| $8.38M | 2.24% |
+2,594,536
| New | +$7.05M |
|
19
Spyre Therapeutics
SYRE
$8.87B
| $8.15M | 2.17% |
+378,766
| New | +$5.22M |
|
20
CALL
Teva Pharmaceuticals
TEVA
$35.9B
| $7.32M | 1.95% |
+701,597
| New | +$6.55M |
|
21
Disc Medicine
IRON
$2.83B
| $7.24M | 1.93% |
+125,429
| New | +$6.42M |
|
22
Lantheus
LNTH
$6.82B
| $6.75M | 1.8% |
+108,911
| New | +$7.38M |
|
23
Legend Biotech
LEGN
$4.3B
| $6.3M | 1.68% |
+104,650
| New | +$6.63M |
|
|
ATXS
24
DELISTED
Astria Therapeutics
ATXS
| $6.16M | 1.64% |
+856,952
| New | +$4.74M |
|
25
Insmed
INSM
$23.2B
| $5.38M | 1.44% |
+173,579
| New | +$4.5M |
|
Similar funds
JE
GS
LT
SCM
ETS
CM
SW
SRFM
Stempoint Capital's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Stempoint Capital, which disclosed 67 positions worth $375M. Its ten largest holdings account for 39% of the portfolio.
Its largest position is Roivant Sciences: 2,169,116 shares worth $24.4M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets.
- Stempoint Capital's largest Q4 2023 buy was Roivant Sciences: 2,169,116 shares worth $24.4M.
- Stempoint Capital's ten largest holdings make up 39% of its $375M portfolio in Q4 2023.
- Stempoint Capital disclosed 67 positions in Q4 2023, its first 13F filing on record.
Based on Stempoint Capital's 13F filing for Q4 2023, filed 13 Feb 2024.